Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

264 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Increased Serum Levels of N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) in Mobilized Healthy Donors with G-CSF: A Cohort Study.
Cid J, Guinetti-Ortiz K, Charry P, Carbassé G, de Pablo-Miró M, Rubia L, Garcia M, Alcaraz-Quiles J, Cascos E, Martínez-Cibrian N, Salas MQ, Suárez-Lledó M, Rosiñol L, Fernández-Avilés F, Martínez C, Rovira M, Lozano M. Cid J, et al. Among authors: rosinol l. Transfus Med Rev. 2024 Apr;38(2):150824. doi: 10.1016/j.tmrv.2024.150824. Epub 2024 Mar 15. Transfus Med Rev. 2024. PMID: 38569349
Effect of CD34+ Cell Dose on the Outcomes of Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide.
Pedraza A, Salas MQ, Rodríguez-Lobato LG, Charry P, Suárez-Lledo M, Martínez-Cibrian N, Doménech A, Solano MT, Arcarons J, de Llobet N, Rosiñol L, Gutiérrez-García G, Avilés FF, Urbano-Ispízua Á, Rovira M, Martínez C. Pedraza A, et al. Among authors: rosinol l. Transplant Cell Ther. 2023 Mar;29(3):181.e1-181.e10. doi: 10.1016/j.jtct.2022.12.005. Epub 2022 Dec 14. Transplant Cell Ther. 2023. PMID: 36526259 Free article.
Applicability and validation of different prognostic scores in allogeneic hematopoietic cell transplant (HCT) in the post-transplant cyclophosphamide era.
Salas MQ, Rodríguez-Lobato LG, Charry P, Suárez-Lledó M, Pedraza A, Solano MT, Arcarons J, Cid J, Lozano M, Rosiñol L, Esteve J, Carreras E, Fernández-Avilés F, Martínez C, Rovira M. Salas MQ, et al. Among authors: rosinol l. Hematol Transfus Cell Ther. 2023 Oct 12:S2531-1379(23)00162-1. doi: 10.1016/j.htct.2023.07.008. Online ahead of print. Hematol Transfus Cell Ther. 2023. PMID: 37891074 Free article.
Endothelial Activation and Stress Index in adults undergoing allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide-based prophylaxis.
Escribano-Serrat S, Rodríguez-Lobato LG, Charry P, Martínez-Cibrian N, Suárez-Lledó M, Rivero A, Moreno-Castaño AB, Solano MT, Arcarons J, Nomdedeu M, Cid J, Lozano M, Pedraza A, Rosiñol L, Esteve J, Urbano-Ispizua Á, Palomo M, Fernández-Avilés F, Martínez C, Díaz-Ricart M, Carreras E, Rovira M, Salas MQ. Escribano-Serrat S, et al. Among authors: rosinol l. Cytotherapy. 2024 Jan;26(1):73-80. doi: 10.1016/j.jcyt.2023.10.008. Epub 2023 Nov 10. Cytotherapy. 2024. PMID: 37952139
Post-Transplantation Cyclophosphamide and Tacrolimus for Graft-versus-Host Disease Prevention after Allogeneic Hematopoietic Cell Transplantation from HLA-Matched Donors Has More Advantages Than Limitations.
Salas MQ, Pedraza A, Charry P, Suárez-Lledó M, Rodríguez-Lobato LG, Brusosa M, Solano MT, Serrahima A, Nomdedeu M, Cid J, Lozano M, Arcarons J, de Llobet N, Rosiñol L, Esteve J, Urbano-Ispizua Á, Carreras E, Fernández-Avilés F, Rovira M, Martinez C. Salas MQ, et al. Among authors: rosinol l. Transplant Cell Ther. 2024 Feb;30(2):213.e1-213.e12. doi: 10.1016/j.jtct.2023.11.020. Epub 2023 Nov 30. Transplant Cell Ther. 2024. PMID: 38042256
Impact of letermovir prophylaxis in CMV reactivation and disease after allogenic hematopoietic cell transplantation: a real-world, observational study.
Brusosa M, Ruiz S, Monge I, Solano MT, Rosiñol L, Esteve J, Carreras E, Marcos MÁ, Riu G, Carcelero E, Martinez C, Fernández-Avilés F, Rovira M, Suárez-Lledó M, Salas MQ. Brusosa M, et al. Among authors: rosinol l. Ann Hematol. 2024 Feb;103(2):609-621. doi: 10.1007/s00277-023-05542-6. Epub 2023 Nov 14. Ann Hematol. 2024. PMID: 37957371
Easix Score Correlates With Endothelial Dysfunction Biomarkers and Predicts Risk of Acute Graft-Versus-Host Disease After Allogeneic Transplantation.
Pedraza A, Salas MQ, Rodríguez-Lobato LG, Escribano-Serrat S, Suárez-Lledo M, Martínez-Cebrian N, Solano MT, Arcarons J, Rosiñol L, Gutiérrez-García G, Fernández-Avilés F, Moreno-Castaño AB, Molina P, Pino M, Carreras E, Díaz-Ricart M, Rovira M, Palomo M, Martínez C. Pedraza A, et al. Among authors: rosinol l. Transplant Cell Ther. 2024 Feb;30(2):187.e1-187.e12. doi: 10.1016/j.jtct.2023.11.016. Epub 2023 Nov 23. Transplant Cell Ther. 2024. PMID: 38000709
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
Rosiñol L, Oriol A, Teruel AI, Hernández D, López-Jiménez J, de la Rubia J, Granell M, Besalduch J, Palomera L, González Y, Etxebeste MA, Díaz-Mediavilla J, Hernández MT, de Arriba F, Gutiérrez NC, Martín-Ramos ML, Cibeira MT, Mateos MV, Martínez J, Alegre A, Lahuerta JJ, San Miguel J, Bladé J; Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group. Rosiñol L, et al. Blood. 2012 Aug 23;120(8):1589-96. doi: 10.1182/blood-2012-02-408922. Epub 2012 Jul 12. Blood. 2012. PMID: 22791289 Free article. Clinical Trial.
Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group.
Jiménez-Vicente C, Charry P, Castaño-Diez S, Guijarro F, López-Guerra M, Pérez-Valencia AI, Martinez-Roca A, Cortés-Bullich A, Munárriz D, Solano MT, Rosiñol L, Carreras E, Urbano-Ispizua Á, Fernández-Avilés F, Martinez C, Suárez-Lledó M, Díaz-Beyá M, Rovira M, Salas MQ, Esteve J. Jiménez-Vicente C, et al. Among authors: rosinol l. Br J Haematol. 2024 May 29. doi: 10.1111/bjh.19518. Online ahead of print. Br J Haematol. 2024. PMID: 38811025
Effects of CYP3A5 Genotype on Tacrolimus Pharmacokinetics and Graft-versus-Host Disease Incidence in Allogeneic Hematopoietic Stem Cell Transplantation.
Marco DN, Molina M, Guio AM, Julian J, Fortuna V, Fabregat-Zaragoza VL, Salas MQ, Monge-Escartín I, Riu-Viladoms G, Carcelero E, Roma JR, Llobet N, Arcarons J, Suárez-Lledó M, Rosiñol L, Fernández-Avilés F, Rovira M, Brunet M, Martínez C. Marco DN, et al. Among authors: rosinol l. Pharmaceuticals (Basel). 2024 Apr 25;17(5):553. doi: 10.3390/ph17050553. Pharmaceuticals (Basel). 2024. PMID: 38794124 Free PMC article.
264 results